Theres talk of tougher price negotiations and transparency for drug costs, and programs to promote biosimilars (near-identical, lower-cost versions of biologic drugs) now that, for example, Similarly, for GLP-1s, as multiple brands compete and potentially as patents expire down the line we may see prices stabilize or drop
77X07: Surface radiation therapy, superficial, delivery, 150-500 kV, per fraction
Although there is still a lack of expert consensus and guidelines for the diagnosis of MC4R -deficient obesity are currently lacking, preliminary screening for suspected MC4R variant carriers can be accomplished by accurate identification of patients typical clinical features
On rare occasions, it can produce features similar to primary biliary cirrhosis due to progressive destruction of small bile ducts (vanishing duct syndrome)
Products CMS considers to be skin substitutes may also meet FDA's definition of a biological product, either directly or as an analogous product